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An extraordinary faculty of world leaders converged in Toronto at the Glaucoma Risk and Disease Management Symposium on 
October 18
th, 2008, to discuss advances in our knowledge regarding predictors of glaucoma development and clinical course. 
The meeting opened with the 3
rd Research for Sight Keynote Lecture by Dr. Stanley Prusiner, Nobel Prize winner and 
innovator, who described his exciting scientific discovery of Prions, and provoked discussion regarding glaucomatous neural 
degeneration.  The articles in this Open Ophthalmology issue highlight key topics addressed by leading glaucoma experts, and 
provide an educational framework for the reader to become familiar with the latest knowledge related to biomarkers of 
glaucoma, and disease management approaches.  
Major questions addressed in this issue are: What do we really know about the relationship between primary open angle 
glaucoma and intraocular pressure? What are risk calculators for glaucoma and why do we need them?  Should we pay more 
attention to nutritional factors in glaucoma? How can vascular risk factors be weighed in the management of glaucoma?  Will 
gene discoveries in glaucoma help us to assess susceptibilities in individual patients? What are the pearls and pitfalls of optic 
nerve assessment? How can we stage visual fields and why? How is the clinician to know if glaucoma is worsening? What is 
the best approach to stepping up care when the disease progresses?  Is targeted therapy for pseudo-exfoliation a treatment 
option?  
Biomarkers are biological quantitative measurements that may differentiate suspected disease from healthy individuals, and 
predict the course of disease, or treatment response. We know some of the risk factors for glaucoma, such as elevated 
intraocular pressure, though not always present. A combination of 2 or more biomarkers such as optic nerve structure, visual 
function and intraocular pressure, is a “biosignature” of glaucoma disease, just as measurements of high density lipoprotein 
(HDL), low density protein (LDL), and cholesterol have become biosignatures of cardiovascular disease. 
It is an exciting time for ophthalmology and vision science, as additional risk factors for glaucoma are teased out from under 
the shadow of intraocular pressure. Newly discovered biomarkers validated by prospective clinical trials have the potential to 
transform everyday clinical care, and to provide additional outcome measures for future clinical trials. Their pursuit may lead 
us to new insights regarding the etiology and pathogenesis of glaucoma, and spur novel treatments to prevent blindness. It is 
hoped that this unique collection of articles responds to the need to keep up with the rapidly evolving field of glaucoma risk and 
management.  
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